No Data
No Data
Express News | Octagon Capital Advisors LP Reports 9.7% Passive Stake in Allovir Inc as of Sept 30-SEC Filing
Maintaining Hold on AlloVir Amid Financial Performance and Strategic Uncertainty
Morgan Stanley Maintains AlloVir(ALVR.US) With Sell Rating, Maintains Target Price $0.5
Morgan Stanley Sticks to Its Sell Rating for AlloVir (ALVR)
AlloVir | 10-Q: Q2 2024 Earnings Report
Here's Why AlloVir (NASDAQ:ALVR) Must Use Its Cash Wisely
No Data
No Data